High intramuscular adipose tissue content was a favorable prognostic factor in patients with advanced gastric cancer treated with nivolumab monotherapy.

Toshimitsu TanakaKeisuke MiwaYasutaka ShimotsuuraSachiko NagasuHirona ShigyouKeisuke HirotaShunji KoyaYoshito AkagiTakumi Kawaguchi

Published in: Journal of gastroenterology and hepatology (2023)

Immune-related adverse events and high IMAT were favorable factors for OS in patients with AGC treated with nivolumab. Thus, along with irAEs, skeletal muscle quality is important in managing patients with AGC treated with nivolumab.

Keyphrases

prognostic factors
skeletal muscle
adipose tissue
insulin resistance
newly diagnosed
neoadjuvant chemotherapy
randomized controlled trial
open label
clinical trial